This site provides INTERCEPT product information for International audiences Select your region
Though operational practices vary centre by centre, the routine use of INTERCEPT™ pathogen inactivation technology for platelets in Europe has demonstrated significant operational gains that translate into cost savings.
- The replacement of gamma irradiation, cytomegalovirus (CMV) testing, and bacterial detection with pathogen inactivation can result in an estimated savings of €20 to €30 per platelet unit.1,2
- The ability to prolong platelet storage in some countries with pathogen inactivation enables centres to reduce discard rates. Assuming an improvement of wastage by 10% and an average platelet unit price of €250 to €600, increased shelf life could save €25 to €60 per unit.3,4
- Pathogen inactivation mitigates the differential risk attained between apheresis and whole-blood derived platelets; thus providing the ability to achieve savings via an optimised production ratio in terms of collection methods.5,6,7,8,14
- The amortisation of costs for a pathogen inactivation kit over more than one therapeutic unit through double dose apheresis collections decreases costs per kit by 50%.9
- Significant savings have been modeled for the reduction of acute transfusion reactions, and when using pathogen inactivation as insurance against unknown pathogens.10,11,12,
- The double dose buffy coat platelet production process can contribute significantly to the affordability of the INTERCEPTTM Blood System for platelets, and in some cases, may allow blood centres to implement pathogen inactivation in a cost-neutral or even a cost-saving way.